-
1
-
-
37549032137
-
Immunological aspects of cancer chemotherapy
-
Zitvogel, L., L. Apetoh, F. Ghiringhelli, and G. Kroemer. 2008. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8: 59-73.
-
(2008)
Nat. Rev. Immunol.
, vol.8
, pp. 59-73
-
-
Zitvogel, L.1
Apetoh, L.2
Ghiringhelli, F.3
Kroemer, G.4
-
2
-
-
34948820602
-
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
-
Apetoh, L., F. Ghiringhelli, A. Tesniere, M. Obeid, C. Ortiz, A. Criollo, G Mignot, M. C. Maiuri, E. Ullrich, P. Saulnier, et al. 2007. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13: 1050-1059.
-
(2007)
Nat. Med.
, vol.13
, pp. 1050-1059
-
-
Apetoh, L.1
Ghiringhelli, F.2
Tesniere, A.3
Obeid, M.4
Ortiz, C.5
Criollo, A.6
Mignot, G.7
Maiuri, M.C.8
Ullrich, E.9
Saulnier, P.10
-
3
-
-
33846057130
-
Calreticulin exposure dictates the immunogenicity of cancer cell death
-
Obeid, M., A. Tesniere, F Ghiringhelli, G. M. Fimia, L. Apetoh, J. L. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, et al. 2007. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat. Med. 13: 54-61.
-
(2007)
Nat. Med.
, vol.13
, pp. 54-61
-
-
Obeid, M.1
Tesniere, A.2
Ghiringhelli, F.3
Fimia, G.M.4
Apetoh, L.5
Perfettini, J.L.6
Castedo, M.7
Mignot, G.8
Panaretakis, T.9
Casares, N.10
-
4
-
-
70350569295
-
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors
-
Ghiringhelli, F, L. Apetoh, A. Tesniere, L. Aymeric, Y. Ma, C. Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, et al. 2009. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β-dependent adaptive immunity against tumors. Nat. Med. 15: 1170-1178.
-
(2009)
Nat. Med.
, vol.15
, pp. 1170-1178
-
-
Ghiringhelli, F.1
Apetoh, L.2
Tesniere, A.3
Aymeric, L.4
Ma, Y.5
Ortiz, C.6
Vermaelen, K.7
Panaretakis, T.8
Mignot, G.9
Ullrich, E.10
-
5
-
-
79551523389
-
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis
-
Schiavoni, G., A. Sistigu, M. Valentini, F Mattei, P. Sestili, F Spadaro, M. Sanchez, S. Lorenzi, M. T. D'Urso, F Belardelli, et al. 2011. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71: 768-778.
-
(2011)
Cancer Res.
, vol.71
, pp. 768-778
-
-
Schiavoni, G.1
Sistigu, A.2
Valentini, M.3
Mattei, F.4
Sestili, P.5
Spadaro, F.6
Sanchez, M.7
Lorenzi, S.8
D'Urso, M.T.9
Belardelli, F.10
-
6
-
-
16844379997
-
Immunosuppressive networks in the tumour environment and their therapeutic relevance
-
Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
-
(2005)
Nat. Rev. Cancer
, vol.5
, pp. 263-274
-
-
Zou, W.1
-
8
-
-
67349250111
-
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: A role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy
-
van der Most, R. G., A. J. Currie, S. Mahendran, A. Prosser, A. Darabi, B. W. Robinson, A. K. Nowak, and R. A. Lake. 2009. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol. Immunother. 58: 1219-1228.
-
(2009)
Cancer Immunol. Immunother.
, vol.58
, pp. 1219-1228
-
-
Van Der Most, R.G.1
Currie, A.J.2
Mahendran, S.3
Prosser, A.4
Darabi, A.5
Robinson, B.W.6
Nowak, A.K.7
Lake, R.A.8
-
10
-
-
65549141834
-
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor mi-croenvironment for immune-based cancer therapies
-
Ozao-Choy, J., G. Ma, J. Kao, G. X. Wang, M. Meseck, M. Sung, M. Schwartz, C. M. Divino, R Y. Pan, and S. H. Chen. 2009. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor mi-croenvironment for immune-based cancer therapies. Cancer Res. 69: 2514-2522.
-
(2009)
Cancer Res.
, vol.69
, pp. 2514-2522
-
-
Ozao-Choy, J.1
Ma, G.2
Kao, J.3
Wang, G.X.4
Meseck, M.5
Sung, M.6
Schwartz, M.7
Divino, C.M.8
Pan, R.Y.9
Chen, S.H.10
-
11
-
-
84892686102
-
Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer
-
Alizadeh, D., M. Trad, N. T. Hanke, C. B. Larmonier, N. Janikashvili, B. Bonnotte, E. Katsanis, and N. Larmonier. 2014. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer. Cancer Res. 74: 104-118.
-
(2014)
Cancer Res.
, vol.74
, pp. 104-118
-
-
Alizadeh, D.1
Trad, M.2
Hanke, N.T.3
Larmonier, C.B.4
Janikashvili, N.5
Bonnotte, B.6
Katsanis, E.7
Larmonier, N.8
-
12
-
-
77951086882
-
5-fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity
-
Vincent, J., G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, A. Chevriaux, F. Martin, L. Apetoh, C. Rébé, and F. Ghiringhelli. 2010. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70: 3052-3061.
-
(2010)
Cancer Res.
, vol.70
, pp. 3052-3061
-
-
Vincent, J.1
Mignot, G.2
Chalmin, F.3
Ladoire, S.4
Bruchard, M.5
Chevriaux, A.6
Martin, F.7
Apetoh, L.8
Rébé, C.9
Ghiringhelli, F.10
-
13
-
-
77956680680
-
A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
-
Kodumudi, K. N., K. Woan, D. L. Gilvary, E. Sahakian, S. Wei, and J. Y. Djeu. 2010. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16: 4583-4594.
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 4583-4594
-
-
Kodumudi, K.N.1
Woan, K.2
Gilvary, D.L.3
Sahakian, E.4
Wei, S.5
Djeu, J.Y.6
-
14
-
-
79956085853
-
Unraveling cancer chemo-immunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide
-
Moschella, F, M. Valentini, E. Aricô, I. Macchia, P. Sestili, M. T. D'Urso, C. Alessandri, F Belardelli, and E. Proietti. 2011. Unraveling cancer chemo-immunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res. 71: 3528-3539.
-
(2011)
Cancer Res.
, vol.71
, pp. 3528-3539
-
-
Moschella, F.1
Valentini, M.2
Aricô, E.3
Macchia, I.4
Sestili, P.5
D'Urso, M.T.6
Alessandri, C.7
Belardelli, F.8
Proietti, E.9
-
15
-
-
84880733312
-
Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology
-
Kalos, M., and C. H. June. 2013. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39: 49-60.
-
(2013)
Immunity
, vol.39
, pp. 49-60
-
-
Kalos, M.1
June, C.H.2
-
16
-
-
84890147150
-
Exploiting the curative potential of adoptive T-cell therapy for cancer
-
Hinrichs, C. S., and S. A. Rosenberg. 2014. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol. Rev. 257: 56-71.
-
(2014)
Immunol. Rev.
, vol.257
, pp. 56-71
-
-
Hinrichs, C.S.1
Rosenberg, S.A.2
-
17
-
-
0021826670
-
+,2 T cells. Tumor eradication does not require participation of cytotoxic T cells
-
+,2 T cells. Tumor eradication does not require participation of cytotoxic T cells. J. Exp. Med. 161: 1122-1134.
-
(1985)
J. Exp. Med.
, vol.161
, pp. 1122-1134
-
-
Greenberg, P.D.1
Kern, D.E.2
Cheever, M.A.3
-
18
-
-
77949522803
-
+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
-
+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207: 637-650.
-
(2010)
J. Exp. Med.
, vol.207
, pp. 637-650
-
-
Quezada, S.A.1
Simpson, T.R.2
Peggs, K.S.3
Merghoub, T.4
Vider, J.5
Fan, X.6
Blasberg, R.7
Yagita, H.8
Muranski, P.9
Antony, P.A.10
-
19
-
-
77949530108
-
+ T cells differentiated in vivo eradicate established melanoma
-
+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 207: 651-667.
-
(2010)
J. Exp. Med.
, vol.207
, pp. 651-667
-
-
Xie, Y.1
Akpinarli, A.2
Maris, C.3
Hipkiss, E.L.4
Lane, M.5
Kwon, E.K.6
Muranski, P.7
Restifo, N.P.8
Antony, P.A.9
-
20
-
-
84900301377
-
+ T cells in a patient with epithelial cancer
-
+ T cells in a patient with epithelial cancer. Science 344: 641-645.
-
(2014)
Science
, vol.344
, pp. 641-645
-
-
Tran, E.1
Turcotte, S.2
Gros, A.3
Robbins, P.F.4
Lu, Y.C.5
Dudley, M.E.6
Wunderlich, J.R.7
Somerville, R.P.8
Hogan, K.9
Hinrichs, C.S.10
-
21
-
-
0032473562
-
Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
-
Ossendorp, F, E. Mengedé, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702.
-
(1998)
J. Exp. Med.
, vol.187
, pp. 693-702
-
-
Ossendorp, F.1
Mengedé, E.2
Camps, M.3
Filius, R.4
Melief, C.J.5
-
23
-
-
0037174674
-
Cancer regression and autoimmunity in patients after clonal re-population with antitumor lymphocytes
-
Dudley, M. E., J. R. Wunderlich, P. F Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal re-population with antitumor lymphocytes. Science 298: 850-854.
-
(2002)
Science
, vol.298
, pp. 850-854
-
-
Dudley, M.E.1
Wunderlich, J.R.2
Robbins, P.F.3
Yang, J.C.4
Hwu, P.5
Schwartzentruber, D.J.6
Topalian, S.L.7
Sherry, R.8
Restifo, N.P.9
Hubicki, A.M.10
-
24
-
-
20244389660
-
Critical role of the thl/Tcl circuit for the generation of tumor-specific CTL during tumor eradication in vivo by thl-cell therapy
-
Chamoto, K., A. Kosaka, T. Tsuji, J. Matsuzaki, T. Sato, T Takeshima, K. Iwakabe, Y Togashi, T. Koda, and T. Nishimura. 2003. Critical role of the Thl/Tcl circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Thl-cell therapy. Cancer Sci. 94: 924-928.
-
(2003)
Cancer Sci.
, vol.94
, pp. 924-928
-
-
Chamoto, K.1
Kosaka, A.2
Tsuji, T.3
Matsuzaki, J.4
Sato, T.5
Takeshima, T.6
Iwakabe, K.7
Togashi, Y.8
Koda, T.9
Nishimura, T.10
-
25
-
-
34249677872
-
+ TEs provides intratumoral TE proliferation and synergistic antitumor response
-
+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 109: 4865-4876.
-
(2007)
Blood
, vol.109
, pp. 4865-4876
-
-
Wang, L.X.1
Shu, S.2
Disis, M.L.3
Plautz, G.E.4
-
26
-
-
45549099784
-
+ T cells against NY-ESO-1
-
+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
-
(2008)
N. Engl. J. Med.
, vol.358
, pp. 2698-2703
-
-
Hunder, N.N.1
Wallen, H.2
Cao, J.3
Hendricks, D.W.4
Reilly, J.Z.5
Rodmyre, R.6
Jungbluth, A.7
Gnjatic, S.8
Thompson, J.A.9
Yee, C.10
-
27
-
-
68049118838
-
Immunity to murine prostatic tumors: Continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells
-
Shafer-Weaver, K. A., S. K. Watkins, M. J. Anderson, L. J. Draper, A. Malyguine, W. G. Alvord, N. M. Greenberg, and A. A. Hurwitz. 2009. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res. 69: 6256-6264.
-
(2009)
Cancer Res.
, vol.69
, pp. 6256-6264
-
-
Shafer-Weaver, K.A.1
Watkins, S.K.2
Anderson, M.J.3
Draper, L.J.4
Malyguine, A.5
Alvord, W.G.6
Greenberg, N.M.7
Hurwitz, A.A.8
-
30
-
-
15244338630
-
+ T cells
-
+ T cells. Immunity 22: 371-383.
-
(2005)
Immunity
, vol.22
, pp. 371-383
-
-
Corthay, A.1
Skovseth, D.K.2
Lundin, K.U.3
Røsjø, E.4
Omholt, H.5
Hofgaard, P.O.6
Haraldsen, G.7
Bogen, B.8
-
31
-
-
34249990107
-
CD4 cells can be more efficient at tumor rejection than CD8 cells
-
Perez-Diez, A., N. T Joncker, K Choi, W. F Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354.
-
(2007)
Blood
, vol.109
, pp. 5346-5354
-
-
Perez-Diez, A.1
Joncker, N.T.2
Choi, K.3
Chan, W.F.4
Anderson, C.C.5
Lantz, O.6
Matzinger, P.7
-
35
-
-
0032170052
-
Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation
-
Guillaume, T., D. B. Rubinstein, and M. Symann. 1998. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 92: 1471-1490.
-
(1998)
Blood
, vol.92
, pp. 1471-1490
-
-
Guillaume, T.1
Rubinstein, D.B.2
Symann, M.3
-
36
-
-
85027957593
-
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
-
Sistigu, A., S. Viaud, N Chaput, L. Bracci, E. Proietti, and L. Zitvogel. 2011. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin. Immunopathol. 33: 369-383.
-
(2011)
Semin. Immunopathol.
, vol.33
, pp. 369-383
-
-
Sistigu, A.1
Viaud, S.2
Chaput, N.3
Bracci, L.4
Proietti, E.5
Zitvogel, L.6
-
37
-
-
84863858208
-
Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide
-
Salem, M. L., A. A. Al-Khami, S. A. El-Nagaar, A. A. Zidan, I. M. Al-Sharkawi, C. Marcela Diaz-Montero, and D. J. Cole. 2012. Kinetics of rebounding of lymphoid and myeloid cells in mouse peripheral blood, spleen and bone marrow after treatment with cyclophosphamide. Cell. Immunol. 276: 67-74.
-
(2012)
Cell. Immunol.
, vol.276
, pp. 67-74
-
-
Salem, M.L.1
Al-Khami, A.A.2
El-Nagaar, S.A.3
Zidan, A.A.4
Al-Sharkawi, I.M.5
Marcela Diaz-Montero, C.6
Cole, D.J.7
-
38
-
-
77949889975
-
Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a flt3 ligand-dependent expansion of dendritic cells
-
Salem, M. L., A. A. Al-Khami, S. A. El-Naggar, C. M. Dfaz-Montero, Y Chen, and D. J. Cole. 2010. Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells. J. Immunol. 184: 1737-1747.
-
(2010)
J. Immunol.
, vol.184
, pp. 1737-1747
-
-
Salem, M.L.1
Al-Khami, A.A.2
El-Naggar, S.A.3
Dfaz-Montero, C.M.4
Chen, Y.5
Cole, D.J.6
-
39
-
-
77958489808
-
Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces
-
Sonnenberg, G. F, L. A. Fouser, and D. Artis. 2010. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv. Immunol. 107: 1-29.
-
(2010)
Adv. Immunol.
, vol.107
, pp. 1-29
-
-
Sonnenberg, G.F.1
Fouser, L.A.2
Artis, D.3
-
40
-
-
0026643596
-
Interleukin-5, eosinophils, and disease
-
Sanderson, C. J. 1992. Interleukin-5, eosinophils, and disease. Blood 79: 3101-3109.
-
(1992)
Blood
, vol.79
, pp. 3101-3109
-
-
Sanderson, C.J.1
-
41
-
-
84867905099
-
IL-1 family members IL-18 and IL-33 up-regulate the inflammatory potential of differentiated human thl and th2 cultures
-
Blom, L., and L. K. Poulsen. 2012. IL-1 family members IL-18 and IL-33 up-regulate the inflammatory potential of differentiated human Thl and Th2 cultures. J. Immunol. 189: 4331-4337.
-
(2012)
J. Immunol.
, vol.189
, pp. 4331-4337
-
-
Blom, L.1
Poulsen, L.K.2
-
43
-
-
0020593560
-
Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth
-
Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15: 101-107.
-
(1983)
Cancer Immunol. Immunother.
, vol.15
, pp. 101-107
-
-
Ben-Efraim, S.1
Bocian, R.C.2
Mokyr, M.B.3
Dray, S.4
-
44
-
-
8944220233
-
A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
-
Attal, M., J. L. Harousseau, A. M. Stoppa, J. J. Sotto, J. G. Fuzibet, J. F Rossi, P. Casassus, H. Maisonneuve, T. Facon, N. Ifrah, et al; Intergroupe Français du Myelome. 1996. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N. Engl. J. Med 335: 91-97.
-
(1996)
N. Engl. J. Med
, vol.335
, pp. 91-97
-
-
Attal, M.1
Harousseau, J.L.2
Stoppa, A.M.3
Sotto, J.J.4
Fuzibet, J.G.5
Rossi, J.F.6
Casassus, P.7
Maisonneuve, H.8
Facon, T.9
Ifrah, N.10
-
45
-
-
15044338886
-
Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation
-
Lindemann, M., P. Schuett, T Moritz, H. D. Ottinger, B. Opalka, S. Seeber, M. R. Nowrousian, and H. Grosse-Wilde. 2005. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia 19: 490-492.
-
(2005)
Leukemia
, vol.19
, pp. 490-492
-
-
Lindemann, M.1
Schuett, P.2
Moritz, T.3
Ottinger, H.D.4
Opalka, B.5
Seeber, S.6
Nowrousian, M.R.7
Grosse-Wilde, H.8
-
46
-
-
0032519429
-
Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor
-
Mokyr, M. B., T. V Kalinichenko, L. Gorelik, and J. A. Bluestone. 1998. Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor. J. Immunol. 160: 1866-1874.
-
(1998)
J. Immunol.
, vol.160
, pp. 1866-1874
-
-
Mokyr, M.B.1
Kalinichenko, T.V.2
Gorelik, L.3
Bluestone, J.A.4
-
47
-
-
0034660469
-
Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
-
Sojka, D. K., M. Donepudi, J. A. Bluestone, and M. B. Mokyr. 2000. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells. J. Immunol. 164: 6230-6236.
-
(2000)
J. Immunol.
, vol.164
, pp. 6230-6236
-
-
Sojka, D.K.1
Donepudi, M.2
Bluestone, J.A.3
Mokyr, M.B.4
-
48
-
-
0033917007
-
B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells
-
Sojka, D. K., R. N. La Motte, and M. B. Mokyr. 2000. B7-2 expression on tumor cells is important for the acquisition of cytotoxic T lymphocyte activity by spleen cells from low-dose-melphalan-treated MOPC-315 tumor bearers via a mechanism that requires either B7-1 or B7-2 expression on host antigen-presenting cells. Cancer Immunol. Immunother. 49: 10-22.
-
(2000)
Cancer Immunol. Immunother.
, vol.49
, pp. 10-22
-
-
Sojka, D.K.1
La Motte, R.N.2
Mokyr, M.B.3
-
49
-
-
0037382989
-
Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells
-
Donepudi, M., V M. Jovasevic, P. Raychaudhuri, and M. B. Mokyr. 2003. Melphalan-induced up-regulation of B7-1 surface expression on normal splenic B cells. Cancer Immunol. Immunother. 52: 162-170.
-
(2003)
Cancer Immunol. Immunother.
, vol.52
, pp. 162-170
-
-
Donepudi, M.1
Jovasevic, V.M.2
Raychaudhuri, P.3
Mokyr, M.B.4
-
50
-
-
33847368549
-
+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
-
+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56: 641-648.
-
(2007)
Cancer Immunol. Immunother.
, vol.56
, pp. 641-648
-
-
Ghiringhelli, F.1
Menard, C.2
Puig, P.E.3
Ladoire, S.4
Roux, S.5
Martin, F.6
Solary, E.7
Le Cesne, A.8
Zitvogel, L.9
Chauffert, B.10
-
52
-
-
76249097336
-
Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodeple-tion in patients with multiple myeloma: A window for adoptive immunotherapy
-
Condomines, M., J. L. Veyrune, M. Larroque, P. Quittet, P. Latry, C. Lugagne, C. Hertogh, T. Kanouni, J. F Rossi, and B. Klein. 2010. Increased plasma-immune cytokines throughout the high-dose melphalan-induced lymphodeple-tion in patients with multiple myeloma: a window for adoptive immunotherapy. J. Immunol. 184: 1079-1084.
-
(2010)
J. Immunol.
, vol.184
, pp. 1079-1084
-
-
Condomines, M.1
Veyrune, J.L.2
Larroque, M.3
Quittet, P.4
Latry, P.5
Lugagne, C.6
Hertogh, C.7
Kanouni, T.8
Rossi, J.F.9
Klein, B.10
-
53
-
-
30744454570
-
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer
-
Rapoport, A. P., E. A. Stadtmauer, N. Aqui, A. Badros, J. Cotte, L. Chrisley, E. Veloso, Z. Zheng, S. Westphal, R. Mair, et al. 2005. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11: 1230-1237.
-
(2005)
Nat. Med.
, vol.11
, pp. 1230-1237
-
-
Rapoport, A.P.1
Stadtmauer, E.A.2
Aqui, N.3
Badros, A.4
Cotte, J.5
Chrisley, L.6
Veloso, E.7
Zheng, Z.8
Westphal, S.9
Mair, R.10
-
54
-
-
67650360757
-
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells
-
Rapoport, A. P., E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H. B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. 2009. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 15: 4499-4507.
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 4499-4507
-
-
Rapoport, A.P.1
Stadtmauer, E.A.2
Aqui, N.3
Vogl, D.4
Chew, A.5
Fang, H.B.6
Janofsky, S.7
Yager, K.8
Veloso, E.9
Zheng, Z.10
-
55
-
-
84903990337
-
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis
-
Ding, Z. C, X. Lu, M. Yu, H. Lemos, L. Huang, P. Chandler, K. Liu, M. Walters, A. Krasinski, M. Mack, et al. 2014. Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer Res. 74: 3441-3453.
-
(2014)
Cancer Res.
, vol.74
, pp. 3441-3453
-
-
Ding, Z.C.1
Lu, X.2
Yu, M.3
Lemos, H.4
Huang, L.5
Chandler, P.6
Liu, K.7
Walters, M.8
Krasinski, A.9
Mack, M.10
-
56
-
-
84900846179
-
+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules?
-
+ T cells detect and eliminate tumor cells that either lack or express MHC class II molecules? Front. Immunol. 5: 174.
-
(2014)
Front. Immunol.
, vol.5
, pp. 174
-
-
Haabeth, O.A.1
Tveita, A.A.2
Fauskanger, M.3
Schjesvold, F.4
Lorvik, K.B.5
Hofgaard, P.O.6
Omholt, H.7
Munthe, L.A.8
Dembic, Z.9
Corthay, A.10
Bogen, B.11
|